Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

Artificial intelligence continues stirring things up in chemistry. To wit: Y Combinator-backed Cambridge, U.K.-based ...

Werner held roles at Bristol Myers Squibb, AstraZeneca and Novartis before landing at Alltrna, where she works to develop tRNA-based treatments for a range of diseases.

A team of chemists, biologists and microbiologists led by researchers in Arts & Sciences at Washington University in St.

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Blujepa is the first new type of oral antibiotic to treat UTIs to gain approval in more than 20 years. Its development was ...

A groundbreaking type of artificial intelligence (AI) could speed up new drug development by around six years, researchers say. Cancer patients could get access to new medicines in half the ...

Every few days, doctors needed to drain liters of fluid ... There isn’t typically much money to be made developing a new drug ...

Experts say the approach could also save millions of pounds by cutting projects or clinical trials that would otherwise fail. By contributor Jane Kirby, PA Health Editor Published Mar 19 ...

Microsoft, Amazon and Google are investing billions of dollars in quantum computing. So what chance does Australia have?

Artificial intelligence continues stirring things up in chemistry. To wit: Y Combinator-backed Cambridge, U.K.-based ReactWise is using AI to speed up chemical manufacturing — a key step in ...